Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236122307> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4236122307 endingPage "5082" @default.
- W4236122307 startingPage "5082" @default.
- W4236122307 abstract "5082 Background: Recurrent AOC patients (pts) often receive several CT lines, some of which have detrimental impact on life quality and high cost. VP16 and G are well tolerated, active, relatively unexpensive drugs; VP16 can be given orally. We evaluated the activity and the toxicity of this combination in platinum resistant pts. Methods: 27 AOC pts received i.v.G 1000 mg/sqm d.1 and 8 and VP16 p.o. 100 mg/day for 5 days (d.8 – 12) every 21 days. All pts were pretreated with platinum/taxol (PT) regimens (5 pts did not receive Taxol due to allergic reaction) and were primary (disease progression (PD) during PT) (16 pts) or secondary (DDP sensible pts re-treated with more than 2 CT lines) (11 pts) DDP-R; 13 pts received G-VP16 as second line whereas this was a third or more advanced line treatment for 14 pts. Topotecan and/or Pegylated Doxorubicin were used before this treatment. Median age was 65 yrs (range 30 – 82) and median ECOG PS was 0 (range 0 – 1). Results: In 2 pts CT was stopped after 1 course due to intolerance to G (skin reaction) and in 5 pts is still ongoing. In 20 evaluable pts, 4 complete (20%) and 9 (45%) partial responses were observed (objective response rate = 65%); 5 pts had disease stabilization (25%) while 2 pts exhibited PD (10%).Median response duration was 6 months (range 1–14). Only WHO grade 3 leucopenia in 1 pt and thrombocytopenia in 2 pts were observed; no supportive G-CSF therapy or hospitalisation was required. Conclusions: G-VP16 seems to be a promising, well tolerated and low expensive second line CT for DDP-R AOC pts. No significant financial relationships to disclose." @default.
- W4236122307 created "2022-05-12" @default.
- W4236122307 creator A5001753228 @default.
- W4236122307 creator A5009553750 @default.
- W4236122307 creator A5018858868 @default.
- W4236122307 creator A5043044349 @default.
- W4236122307 creator A5061677202 @default.
- W4236122307 creator A5070738538 @default.
- W4236122307 creator A5082530268 @default.
- W4236122307 date "2004-07-15" @default.
- W4236122307 modified "2023-09-26" @default.
- W4236122307 title "Second line chemotherapy (CT) with gemcitabine (G) and vepesid (VP16) in platinum resistant (DDP-R) advanced ovarian cancer (AOC) patients" @default.
- W4236122307 doi "https://doi.org/10.1200/jco.2004.22.90140.5082" @default.
- W4236122307 hasPublicationYear "2004" @default.
- W4236122307 type Work @default.
- W4236122307 citedByCount "0" @default.
- W4236122307 crossrefType "journal-article" @default.
- W4236122307 hasAuthorship W4236122307A5001753228 @default.
- W4236122307 hasAuthorship W4236122307A5009553750 @default.
- W4236122307 hasAuthorship W4236122307A5018858868 @default.
- W4236122307 hasAuthorship W4236122307A5043044349 @default.
- W4236122307 hasAuthorship W4236122307A5061677202 @default.
- W4236122307 hasAuthorship W4236122307A5070738538 @default.
- W4236122307 hasAuthorship W4236122307A5082530268 @default.
- W4236122307 hasConcept C126322002 @default.
- W4236122307 hasConcept C141071460 @default.
- W4236122307 hasConcept C2776694085 @default.
- W4236122307 hasConcept C2778119113 @default.
- W4236122307 hasConcept C2780258809 @default.
- W4236122307 hasConcept C2781209748 @default.
- W4236122307 hasConcept C71924100 @default.
- W4236122307 hasConcept C90924648 @default.
- W4236122307 hasConceptScore W4236122307C126322002 @default.
- W4236122307 hasConceptScore W4236122307C141071460 @default.
- W4236122307 hasConceptScore W4236122307C2776694085 @default.
- W4236122307 hasConceptScore W4236122307C2778119113 @default.
- W4236122307 hasConceptScore W4236122307C2780258809 @default.
- W4236122307 hasConceptScore W4236122307C2781209748 @default.
- W4236122307 hasConceptScore W4236122307C71924100 @default.
- W4236122307 hasConceptScore W4236122307C90924648 @default.
- W4236122307 hasIssue "14_suppl" @default.
- W4236122307 hasLocation W42361223071 @default.
- W4236122307 hasOpenAccess W4236122307 @default.
- W4236122307 hasPrimaryLocation W42361223071 @default.
- W4236122307 hasRelatedWork W1992396964 @default.
- W4236122307 hasRelatedWork W2141048775 @default.
- W4236122307 hasRelatedWork W2159227061 @default.
- W4236122307 hasRelatedWork W2348439805 @default.
- W4236122307 hasRelatedWork W2363777001 @default.
- W4236122307 hasRelatedWork W2401940525 @default.
- W4236122307 hasRelatedWork W2461409983 @default.
- W4236122307 hasRelatedWork W2471957740 @default.
- W4236122307 hasRelatedWork W3000431466 @default.
- W4236122307 hasRelatedWork W3163726055 @default.
- W4236122307 hasVolume "22" @default.
- W4236122307 isParatext "false" @default.
- W4236122307 isRetracted "false" @default.
- W4236122307 workType "article" @default.